Ivan Henriquez
Overview
Explore the profile of Ivan Henriquez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
209
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henriquez I, Malave B, Lopez Campos F, Hidalgo E, Muelas R, Ferrer C, et al.
Clin Transl Oncol
. 2024 Jul;
27(2):706-715.
PMID: 39073734
Background: Metastatic hormone-sensitive prostate cancer (mHSPC) is treatment-resistant and generally considered incurable. The development of prostate-specific membrane antigen positron emission-computed tomography (PSMA PET/CT) has generated immense expectations due to its...
2.
Gonzalez-San Segundo C, Lopez Campos F, Gomez Iturriaga A, Rodriguez A, Olivera J, Duque-Santana V, et al.
BJU Int
. 2024 Jul;
134(4):568-577.
PMID: 39041411
Background: Salvage radiotherapy (SRT) and androgen-deprivation therapy (ADT) are widely used in routine clinical practice to treat patients with prostate cancer who develop biochemical recurrence (BCR) after radical prostatectomy (RP)....
3.
Corkum M, Buyyounouski M, Chang A, Chung H, Chung P, Cox B, et al.
Radiother Oncol
. 2023 Apr;
184:109672.
PMID: 37059334
Background And Purpose: Local recurrences after previous radiotherapy (RT) are increasingly being identified in biochemically recurrent prostate cancer. Salvage prostate brachytherapy (BT) is an effective and well tolerated treatment option....
4.
Bonet M, Gonzalez D, Baquedano J, Garcia E, Altabas M, Casas F, et al.
Clin Transl Oncol
. 2022 Nov;
25(4):1017-1023.
PMID: 36436177
Background: To reach a consensus on recommendations for the management of high-risk and post-operative non-metastatic prostate cancer by a group of Radiation Oncologists in Catalonia dedicated to prostate cancer. Methods:...
5.
Conde-Estevez D, Henriquez I, Munoz-Rodriguez J, Rodriguez-Vida A
Expert Opin Drug Metab Toxicol
. 2022 Sep;
18(9):601-613.
PMID: 36111393
Introduction: Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are frequently poly-medicated due to age-related and androgen deprivation therapy (ADT)-derived comorbidities. In high-risk patients, androgen receptor inhibitors (ARIs) have shown to...
6.
Henriquez I, Roach 3rd M, Morgan T, Bossi A, Gomez J, Abuchaibe O, et al.
Biomedicines
. 2021 Sep;
9(9).
PMID: 34572433
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients....
7.
Henriquez I, Spratt D, Gomez-Iturriaga A, Abuchaibe O, Counago F
World J Clin Oncol
. 2021 Feb;
12(1):6-12.
PMID: 33552935
Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (PSA) > 2 ng/mL, testosterone castration levels < 1.7 nm/L, and the absence of metastatic lesions on conventional imaging (computed...
8.
Counago F, Lopez-Campos F, Diaz-Gavela A, Almagro E, Fenandez-Pascual E, Henriquez I, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32545454
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa...
9.
Balana C, De Las Penas R, Sepulveda J, Gil-Gil M, Luque R, Gallego O, et al.
J Neurooncol
. 2016 Feb;
127(3):569-79.
PMID: 26847813
We sought to determine the impact of bevacizumab on reduction of tumor size prior to chemoradiotherapy in unresected glioblastoma patients. Patients were randomized 1:1 to receive temozolomide (TMZ arm) or...
10.
Arenas M, Arguis M, Diez-Presa L, Henriquez I, Murcia-Mejia M, Gascon M, et al.
Brachytherapy
. 2015 Oct;
14(6):859-65.
PMID: 26489922
Purpose: Nonmelanoma skin cancer (NMSC) is the commonest cancer in humans. NMSC treatment currently includes surgery, radiation therapy, and topical approaches. The objective was to analyze and compare the outcomes,...